Released on = June 12, 2007, 8:34 am

Press Release Author = David W. Moskowitz MD

Industry = Healthcare

Press Release Summary = ST. LOUIS-June 12, 2007--GenoMed (OTC Pink Sheets GMED), a
Next Generation Disease Management company whose business is public healthT, today
announced that Dame Shirley Bassey has agreed to become the company's first Patron.

Press Release Body = ST. LOUIS-June 12, 2007--GenoMed (OTC Pink Sheets GMED), a Next
Generation Disease Management company whose business is public healthT, today
announced that Dame Shirley Bassey has agreed to become the company's first Patron.

Dame Shirley, Britain\'s most successful female singer, is perhaps best known in the
United States for "Goldfinger," the title song of the 1965 James Bond film. In 2003,
Dame Shirley celebrated 50 years in show business with a CD, "Thank You For The
Years," a Top 20 album in Britain. In recognition of her long career, Ms. Bassey,
who was born in Wales, was made a Dame Commander of the British Empire (the female
equivalent of a Knighthood) in 1999 by Queen Elizabeth II.

Dame Shirley has been very active in charity, raising money for the Royal Welsh
College of Music and Drama, and the Noah's Ark Children's Hospital Appeal in
Britain.

Said GenoMed\'s CEO, David Moskowitz MD, \"Dame Shirley, in my mind and in the minds
of many, is actually a Queen. She embodies the human royalty of merit, talent,
beauty, determination, and graceful aging. She represents the very best that is
within us. By lending her name to GenoMed's effort, Dame Shirley is signaling to the
world that our mission of preventive molecular medicine reflects society\'s highest
aspirations."

Added Dr. Moskowitz, "Our Patrons receive no shares or money from the company. Like
Dame Shirley, they are deservedly world-famous, and simply want to increase global
awareness of GenoMed's mission to delay disease and aging. We are extremely honored
that Dame Shirley has agreed to be our first Patron. And we shall be naming
additional Patrons from time to time."

About GenoMed

GenoMed (www.genomed.com) believes it has found the major aging gene. The company
has already published superior clinical outcomes for diabetes, high blood pressure,
emphysema, West Nile virus encephalitis, pancreatic cancer, psoriasis, and sickle
cell disease. Please contact Dr. Moskowitz at dwmoskowitz@genomed.com if you are
interested in joining the company's Clinical Outcomes Improvement Program (COIP®).

Safe Harbor Statement

This press release contains forward looking statements, including those statements
pertaining to GenoMed, Inc.\'s (the Company\'s) treatments. The words or phrases
\"ought to,\" \"should,\" \"could,\" \"may,\" or similar expressions are intended to
identify \"forward-looking statements\" within the meaning of the Private Securities
Litigation Reform Act of 1995. Actual results could differ materially from those
projected in the forward looking statements as a result of a number of risks and
uncertainties, including but not limited to our research and development being
subject to scientific, economic, regulatory, governmental, and technological
factors. Statements made herein are as of the date of this press release and should
not be relied upon as of any subsequent date. Unless otherwise required by
applicable law, we specifically disclaim any obligation to update any
forward-looking statements to reflect occurrences, developments, unanticipated
events or circumstances after the date of such statement.


Web Site = http://www.genomed.com

Contact Details = GenoMed, Inc.
9666 Olive Blvd., #310
St. Louis, MO 63132
tel. 314.983.9933
dwmoskowitz@genomed.com